NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System
31. Oktober 2024 16:01 ET
|
NeuroOne Medical Technologies Corp
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31,...
NeuroOne® Announces $2.65 Million Equity Financing And $3.0 Million Credit Facility
05. August 2024 09:00 ET
|
NeuroOne Medical Technologies Corp
Proceeds to be used for OneRF commercialization activities and to bridge the Company to the close of a potential distribution arrangement with a strategic partner currently in the diligence process ...
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
10. April 2024 09:00 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving...
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
26. März 2024 09:00 ET
|
NeuroOne Medical Technologies Corp
First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control Limited...
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
07. November 2023 08:00 ET
|
NeuroOne Medical Technologies Corp
Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Product potential for transformative improvement in...
NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System
12. Juni 2023 08:35 ET
|
NeuroOne Medical Technologies Corp
Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the added benefit of temperature control EDEN PRAIRIE,...